(Q36245425)

13 August 2017

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries (English)

1 reference

13 August 2017

1 reference

1 reference

8

Leslie Bernstein

1 reference

13 August 2017

Anthony J Swerdlow

9

0 references

author name string

Michael E Jones

1

1 reference

13 August 2017

Flora E van Leeuwen

2

1 reference

13 August 2017

Wilhelmina E Hoogendoorn

3

1 reference

13 August 2017

Marian Je Mourits

4

1 reference

13 August 2017

Harry Hollema

5

1 reference

13 August 2017

Hester van Boven

6

1 reference

13 August 2017

Michael F Press

7

1 reference

13 August 2017

12 June 2012

1 reference

13 August 2017

Breast Cancer Research

1 reference

13 August 2017

14

1 reference

13 August 2017

3

1 reference

13 August 2017

R91

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr3206

13 August 2017

0 references

cites work

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

The impact on National Death Index ascertainment of limiting submissions to Social Security Administration Death Master File matches in epidemiologic studies of mortality

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Relationship between tamoxifen use and high risk endometrial cancer histologic types

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

A modified poisson regression approach to prospective studies with binary data

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Completeness of cancer and death follow-up obtained through the National Health Service Central Register for England and Wales

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Molecular genetic characterization of tamoxifen-associated endometrial cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Tamoxifen therapy for breast cancer and endometrial cancer risk.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3446354

Risk of endometrial cancer after tamoxifen treatment of breast cancer

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FBCR3206

Prognosis of tamoxifen-associated endometrial cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22691381

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ACOG committee opinion. No. 336: Tamoxifen and uterine cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22691381

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/BCR3206

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

1 reference